Skip header and navigation

Refine By

2 records – page 1 of 1.

Immune system changes during simulated planetary exploration on Devon Island, high arctic.
BMC Immunol. 2007;8:7
Publication Type
Brian Crucian
Pascal Lee
Raymond Stowe
Jeff Jones
Rainer Effenhauser
Raymond Widen
Clarence Sams
Author Affiliation
Wyle Laboratories/NASA-JSC, Houston, Texas 77058, USA.
BMC Immunol. 2007;8:7
Publication Type
Arctic Regions
Biological Markers - blood
CD4-Positive T-Lymphocytes - immunology
CD8-Positive T-Lymphocytes - immunology
Cells, Cultured
Cytokines - analysis - blood - immunology
DNA, Viral - blood
Herpesvirus 4, Human - physiology
Hydrocortisone - blood
Immune System - physiology
Immunoglobulin G - blood
Immunoglobulin M - blood
Reproducibility of Results
Space Flight
Space Simulation
Stress, Physiological
T-Lymphocyte Subsets - immunology
T-Lymphocytes - immunology
Time Factors
Viral Load
Virus Latency
Dysregulation of the immune system has been shown to occur during spaceflight, although the detailed nature of the phenomenon and the clinical risks for exploration class missions have yet to be established. Also, the growing clinical significance of immune system evaluation combined with epidemic infectious disease rates in third world countries provides a strong rationale for the development of field-compatible clinical immunology techniques and equipment. In July 2002 NASA performed a comprehensive immune assessment on field team members participating in the Haughton-Mars Project (HMP) on Devon Island in the high Canadian Arctic. The purpose of the study was to evaluate the effect of mission-associated stressors on the human immune system. To perform the study, the development of techniques for processing immune samples in remote field locations was required. Ten HMP-2002 participants volunteered for the study. A field protocol was developed at NASA-JSC for performing sample collection, blood staining/processing for immunophenotype analysis, whole-blood mitogenic culture for functional assessments and cell-sample preservation on-location at Devon Island. Specific assays included peripheral leukocyte distribution; constitutively activated T cells, intracellular cytokine profiles, plasma cortisol and EBV viral antibody levels. Study timepoints were 30 days prior to mission start, mid-mission and 60 days after mission completion.
The protocol developed for immune sample processing in remote field locations functioned properly. Samples were processed on Devon Island, and stabilized for subsequent analysis at the Johnson Space Center in Houston. The data indicated that some phenotype, immune function and stress hormone changes occurred in the HMP field participants that were largely distinct from pre-mission baseline and post-mission recovery data. These immune changes appear similar to those observed in astronauts following spaceflight.
The immune system changes described during the HMP field deployment validate the use of the HMP as a ground-based spaceflight/planetary exploration analog for some aspects of human physiology. The sample processing protocol developed for this study may have applications for immune studies in remote terrestrial field locations. Elements of this protocol could possibly be adapted for future in-flight immunology studies conducted during space missions.
Cites: Acta Microbiol Hung. 1988;35(4):411-62469283
Cites: J Allergy Clin Immunol. 2003 Jun;111(6):1353-6012789239
Cites: Aviat Space Environ Med. 1991 Dec;62(12):1153-81755796
Cites: J Appl Physiol (1985). 1992 Aug;73(2 Suppl):186S-190S1526949
Cites: J Leukoc Biol. 1993 May;53(5):569-758501396
Cites: J Leukoc Biol. 1993 Sep;54(3):209-138371050
Cites: J Leukoc Biol. 1993 Sep;54(3):253-88371055
Cites: Antimicrob Agents Chemother. 1994 Jan;38(1):1-68141561
Cites: J Appl Physiol (1985). 1995 Mar;78(3):810-37775323
Cites: Exp Cell Res. 1995 Jul;219(1):102-97543050
Cites: Adv Space Res. 1994;14(8):5-911537959
Cites: Pathology. 1995 Apr;27(2):186-907567151
Cites: Immunol Cell Biol. 1995 Aug;73(4):316-207493767
Cites: J Interferon Cytokine Res. 1996 May;16(5):409-158727082
Cites: J Appl Physiol (1985). 1996 Jul;81(1):105-168828652
Cites: Am Clin Lab. 1996 Sep;15(8):30-110163489
Cites: J Biotechnol. 1996 Jun 27;47(2-3):215-228987568
Cites: Immunol Cell Biol. 1997 Jun;75(3):275-839243293
Cites: Acta Astronaut. 1994 Jul;33:143-711539514
Cites: Gravit Space Biol Bull. 1997 Jun;10(2):5-1611540120
Cites: Acta Astronaut. 1995 Oct-Dec;36(8-12):713-811541007
Cites: Acta Astronaut. 1995 Oct-Dec;36(8-12):719-2611541008
Cites: Rev Environ Health. 2003 Jan-Mar;18(1):1-1712875508
Cites: Aviat Space Environ Med. 2003 Dec;74(12):1281-414692473
Cites: Brain Behav Immun. 2004 Sep;18(5):443-5015265537
Cites: Physiologist. 1985 Dec;28(6 Suppl):S213-43938847
Cites: Aviat Space Environ Med. 1987 Oct;58(10):983-63118864
Cites: J Clin Microbiol. 1999 Jan;37(1):132-69854077
Cites: Am J Clin Pathol. 1999 Mar;111(3):387-9610078115
Cites: J Leukoc Biol. 1999 Feb;65(2):179-8610088600
Cites: Cytometry. 1999 Sep 1;37(1):74-8010451509
Cites: Brain Behav Immun. 2005 May;19(3):235-4215797312
Cites: Scand J Clin Lab Invest. 2005;65(5):433-616081365
Cites: Brain Behav Immun. 2005 Nov;19(6):547-5415908177
Cites: J Gravit Physiol. 2004 Jul;11(2):P177-8016237828
Cites: J Immunol Methods. 2005 Oct 30;305(2):107-1916214501
Cites: Ann N Y Acad Sci. 2006 Jun;1069:62-7616855135
Cites: Aviat Space Environ Med. 1999 Dec;70(12):1211-310596777
Cites: Immunopharmacology. 1999 Nov;44(3):273-910598884
Cites: J Med Virol. 2000 Jun;61(2):235-4010797380
Cites: J Interferon Cytokine Res. 2000 Jun;20(6):547-5610888111
Cites: J Infect Dis. 2000 Dec;182(6):1761-411069250
Cites: J Allergy Clin Immunol. 2001 Jan;107(1):160-411150006
Cites: Adv Space Res. 1999;24(6):793-80011542624
Cites: J Gravit Physiol. 1999 Jul;6(1):P33-411543016
Cites: J Immunol Methods. 2001 Jan 1;247(1-2):35-4711150535
Cites: Aviat Space Environ Med. 2001 Oct;72(10):884-9111601551
Cites: Photochem Photobiol. 2001 Oct;74(4):570-811683037
Cites: J Allergy Clin Immunol. 2002 May;109(5):854-711994711
Cites: Nutrition. 2002 Oct;18(10):889-9812361784
Cites: Nutrition. 2002 Oct;18(10):899-90312361785
Cites: Med Sci Sports Exerc. 2002 Dec;34(12):2021-712471311
Cites: Brain Behav Immun. 2002 Dec;16(6):785-9812480507
Cites: Physiologist. 1991 Feb;34(1 Suppl):S52-62047466
PubMed ID
17521440 View in PubMed
Less detail

Prevention of mercuric chloride-induced nephritis in the brown Norway rat by treatment with antibodies against the alpha 4 integrin.
J Immunol. 1994 Sep 1;153(5):2313-20
Publication Type
A. Molina
F. Sánchez-Madrid
T. Bricio
A. Martín
A. Barat
V. Alvarez
F. Mampaso
Author Affiliation
Department of Pathology, Ramón and Cajal Hospital, Madrid, Spain.
J Immunol. 1994 Sep 1;153(5):2313-20
Publication Type
Antibodies, Monoclonal - therapeutic use
Cell Adhesion
DNA, Single-Stranded - immunology
Immunization, Passive
Integrins - physiology
Kidney Glomerulus - immunology
Leukocyte Count
Mercuric Chloride - antagonists & inhibitors
Nephritis - chemically induced
Proteinuria - chemically induced
Rats, Inbred BN
Receptors, Very Late Antigen - physiology
Research Support, Non-U.S. Gov't
T-Lymphocyte Subsets - immunology
HgCl2 induces the synthesis of anti-GBM Abs with the development of glomerular and interstitial nephritis, as well as proteinuria, in the Brown Norway rat. The development of this autoimmune disease is a consequence of the appearance of an autoreactive T cell subset-inducing activation of B cells. The administration to mercury-treated rats of the mouse anti-human VLA alpha 4 HP2/1 mAb, which cross-reacts with the rat homologue integrin, completely abrogated the interstitial cell infiltrates. As demonstrated by peripheral blood analysis, this effect is not a result of the depletion of circulating leukocytes or leukocyte subsets. Interestingly, the administration of Abs specific for the alpha 4 integrin also highly reduced anti-GBM Ab synthesis, thus preventing detectable glomerular deposits and proteinuria. Our results confirm that in vivo alpha 4 functions in adhesive interaction of circulating leukocytes and vascular endothelium, and is centrally important in the extravasation and migration of T lymphocytes to sites of tissue injury. We also found a complete absence of interstitial cell infiltrates, together with a positive glomerular IgG lineal deposition pattern, when anti-GBM Abs were passively transferred to rats pretreated with anti-alpha 4 mAb, thus indicating an independent role of alpha 4 integrin in both extravasation of immune cells and production of autoantibodies. Furthermore, these in vivo findings provide preliminary evidence for the participation of the VLA-4 integrin in mediating the intercellular interaction of leukocytes regulating the production of Abs, most likely through the existence of additional yet unknown ligand(s).
PubMed ID
8051427 View in PubMed
Less detail